一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> International Journal of Molecular Sciences >>article
International Journal of Molecular Sciences

International Journal of Molecular Sciences

IF: 5.6
Download PDF

An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines

Published:15 March 2023 DOI: 10.3390/ijms24065648 PMID: 36982721
Angela Zaccagnino, Bozhena Vynnytska-Myronovska, Michael St?ckle, Kerstin Junker

Abstract

The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term administration with sunitinib. Two sunitinib-resistant cell lines, 786-O/S and Caki-2/S, and the matching 786-O/WT and Caki-2/WT cells were exposed to cabozantinib. The drug response was cell-line-specific. The 786-O/S cells were less growth-inhibited by cabozantinib than 786-O/WT cells (p-value = 0.02). In 786-O/S cells, the high level of phosphorylation of MET and AXL was not affected by cabozantinib. Despite cabozantinib hampering the high constitutive phosphorylation of MET, the Caki-2 cells showed low sensitivity to cabozantinib, and this was independent of sunitinib pretreatment. In both sunitinib-resistant cell lines, cabozantinib increased Src-FAK activation and impeded mTOR expression. The modulation of ERK and AKT was cell-line-specific, mirroring the heterogeneity among the patients. Overall, the MET- and AXL-driven status did not affect cell responsiveness to cabozantinib in the second-line treatment. The activation of Src-FAK might counteract cabozantinib activity and contribute to tumor survival and may be considered an early indicator of therapy response.

Substances (6)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Cabozantinib 849217-68-1 C28H24FN3O5 485 suppliers $7.00-$2167.00
Cabozantinib 849217-68-1 C28H24FN3O5 485 suppliers $7.00-$2167.00
Cabozantinib 849217-68-1 C28H24FN3O5 485 suppliers $7.00-$2167.00
Cabozantinib 849217-68-1 C28H24FN3O5 485 suppliers $7.00-$2167.00
XL184 849217-68-1 - Inquiry
XL184 849217-68-1 - Inquiry

Similar articles

IF:5.3

A preliminary study: the anti-proliferation effect of salidroside on different human cancer cell lines.

Cell Biology and Toxicology Xiaolan Hu, Shuxin Lin,etc Published: 1 December 2010
IF:40.8

Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors

Signal Transduction and Targeted Therapy Zhu, Chaojie,etc Published: 22 November 2024
云阳县| 克什克腾旗| 石渠县| 什邡市| 贵定县| 噶尔县| 来凤县| 南通市| 即墨市| 伽师县| 云阳县| 临颍县| 汉中市| 探索| 化隆| 左云县| 锡林郭勒盟| 沂南县| 石台县| 两当县| 高碑店市| 阿尔山市| 高邮市| 习水县| 周宁县| 大宁县| 岑溪市| 辽宁省| 浪卡子县| 攀枝花市| 长武县| 晋州市| 广灵县| 安达市| 东乡族自治县| 嘉鱼县| 务川| 保亭| 郎溪县| 承德市| 织金县|